Welcome to Amphastar Pharmaceuticals’ Media/News where our Press Releases give you insight into what is happening now at Amphastar and other industry NEWS about our fast-growing, innovative company.
We invite you to learn more about us at news and view postings of upcoming events that we believe are of interest to our customers and investors.
CEO Jack Zhang, Ph.D.
President Jason Shandell, MBA, JD
Corporate Headquarters 11570 6th Street, Rancho Cucamonga, CA., USA
Business Generics, Specialty Pharmaceuticals, APIs
2013 Revenue (USD) $230 mm
Stock Exchange Nasdaq: AMPH
Facilities Over 1.1 million sq. ft. with 5 manufacturing sites
Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA
International Medication Sys., Ltd., So. El Monte, CA
Armstrong Pharmaceuticals, Inc., Canton, MA
Amphastar Nanjing, Nanjing, China
Amphastar France Pharmaceuticals, France
Amphastar is a specialty pharmaceutical company that is engaged in developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation pharmaceutical products.
Most of the products we currently sell are used in hospital or urgent care clinical settings and are primarily sold through group purchasing organizations and drug wholesalers.
We are also currently engaged in the development of our own branded product candidates that build on our scientific expertise in developing generic products.
Utilizing our highly experienced professionals and proven ability to develop and manufacture technically difficult products often with significant barriers to the market and produce our own API that is not readily available, we currently have 16 drug products in the market and a robust pipeline that provides a strong probability of sustained growth.
For Media Information